• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Seattle Genetics wins FDA Breakthrough Therapy Designation for Hodgkin lymphoma treatment

October 2, 2017 By Fink Densford

Seattle Genetics

Seattle Genetics (NSDQ:SGEN) said today that the FDA granted Breakthrough Therapy Designation to its antibody-drug conjugate Adcetris in combination with chemotherapy for treating patients with advanced classical Hodgkin lymphoma.

The approval was based on positive top line results from the company’s phase 3 Echelon-1 clinical trial, which were announced in June.

The Bothell, Wash.-based company said it plans to present full data from the trial at the upcoming American Society of Hematology annual meeting in December.

“The phase 3 Echelon-1 study that supports the Breakthrough Therapy Designation for Adcetris in combination with chemotherapy showed superior activity versus the standard of care chemotherapy regimen in the treatment of frontline advanced classical Hodgkin lymphoma patients. The decision by the FDA to grant this designation recognizes the need for new options that can change the care of people with newly diagnosed advanced Hodgkin lymphoma. The designation supports our goal to make Adcetris available to patients in this setting as soon as possible. We look forward to presenting the data from our phase 3 Echelon-1 trial at the upcoming ASH annual meeting and intend to submit a supplemental Biologics License Application to the FDA before the end of 2017,” prez & CEO Clay Siegall said in a press release.

Seattle Genetics said tis Adcetris is currently being evaluated as the foundation of care for CD30-expressing lymphomas in more than 70 clinical trials, but is currently not approved as a frontline therapy for Hodgkin lymphoma.

In February, Immunomedics (NSDQ:IMMU) said it landed an exclusive global licensing agreement with Seattle Genetics for Immunomedics’ antibody-drug conjugate, IMMU-132, for the treatment of solid tumors. The deal could potentially bring in $2 billion plus royalties for Immunomedics.

Filed Under: Featured, Food & Drug Administration (FDA), Oncology, Research & Development Tagged With: Seattle Genetics

IN CASE YOU MISSED IT

  • Senseonics stock is up as it sticks by revenue guidance
  • MedAlliance wins second FDA IDE nod for drug-coated balloon
  • Wells Fargo downgrades Tandem amid rise of automated insulin delivery competition
  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS